about
Quantification of the gene silencing performances of rationally-designed synthetic small RNAs.The two tryptophans of β2-microglobulin have distinct roles in function and folding and might represent two independent responses to evolutionary pressureDay-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home.2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.A hierarchical Naïve Bayes Model for handling sample heterogeneity in classification problems: an application to tissue microarrays.White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation.Analysing Italian voluntary abortion data using a Bayesian approach to the time series decomposition.Temporal data mining for the quality assessment of hemodialysis services.Inferring gene regulatory networks by integrating static and dynamic data.DT-Planner: an environment for managing dynamic decision problems.Accurate peak list extraction from proteomic mass spectra for identification and profiling studies.A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.TGI-Simulator: a visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug.Characterization of an inducible promoter in different DNA copy number conditions.Bottom-up engineering of biological systems through standard bricks: a modularity study on basic parts and devices.PhosphoHunter: An Efficient Software Tool for Phosphopeptide Identification.Modelling the effects of cell-to-cell variability on the output of interconnected gene networks in bacterial populations.Fermentation of lactose to ethanol in cheese whey permeate and concentrated permeate by engineered Escherichia coliModeling of human tumor xenografts and dose rationale in oncology.Multi-Faceted Characterization of a Novel LuxR-Repressible Promoter Library for Escherichia coli.A BioBrick™-Compatible Vector for Allelic Replacement Using the XylE Gene as Selection Marker.Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches.Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.A minimal model of tumor growth inhibition in combination regimens under the hypothesis of no interaction between drugs.Summarizing probe intensities of affymetrix GeneChip 3' expression arrays taking into account day-to-day variability.Multiplexing and demultiplexing logic functions for computing signal processing tasks in synthetic biology.A minimal model of tumor growth inhibition.A model-based approach to the in vitro evaluation of anticancer activity.A mathematical model to study the effects of drugs administration on tumor growth dynamics.Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.A standard vector for the chromosomal integration and characterization of BioBrick™ parts in Escherichia coli.Half-life measurements of chemical inducers for recombinant gene expression.Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development.Characterization of a synthetic bacterial self-destruction device for programmed cell death and for recombinant proteins releaseReduced sampling schedule for the glucose minimal model: importance of Bayesian estimation.Mathematical modeling of growth and death dynamics of mouse embryonic stem cells irradiated with γ-rays.Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach.Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response.
P50
Q27346857-0BB35792-4248-4C7E-93BA-99A849F43B0EQ27666280-C598FF9B-13C6-4275-8A5F-356C79A8F60BQ30276766-E0D9F11C-51A5-4A3A-BBEE-6A85F65DF903Q30278580-49EA91D2-E116-4E48-9FCB-C54C91C878CFQ30478471-02235961-73CD-4C07-B8C7-FC53F100A298Q30540355-080D9234-87C6-42DF-A11B-8E25AC8AF6E5Q30886789-6301FDD4-413C-42A1-B9CC-63432D5E8BBFQ30989480-856DB284-6CC9-4F9C-9E39-D079AB056514Q31126643-FE4F1590-D6B0-49DA-AFD3-50F7753F084EQ32156275-A52EE049-137A-42C6-AC7D-2CFF510577FDQ33719990-5535DF2E-37F6-4467-9FC5-C8230A8C7C33Q33729213-D138F335-6AEB-4B55-B01C-A11BD5752803Q34049774-774AC644-A649-49F2-9954-6CBD1868F947Q34247945-D74B27B0-75E8-4268-9C74-60D9F8F72926Q34387409-83D42B48-7CB5-4668-95DD-7CF68DCDE2BBQ35021699-AF6360D0-9303-485A-8FA8-5A4B2D8878BAQ35655636-EBBDBFA3-F7FC-4E13-A0DD-4A173C3214D5Q36391774-3B793379-2D96-4223-8B2A-EA35B53EDEC4Q38139472-AD6B214F-6BDB-4E35-B381-7A303B5548FEQ38298715-5C1B1CCE-5325-4F6C-8B76-28A22FDC263BQ38409720-90F32CD8-39C7-48CD-8C01-A775973C68F2Q38699135-04962F38-8F5D-4961-80C2-34875B7FF8EDQ38764274-949495A8-714F-41F6-83F2-19C40C466F03Q38853390-4BABFE25-B555-42B2-A7EF-6E3A03537D79Q39190654-7B8D5507-BCD4-426A-B212-1A896F5CF817Q39350661-F02AAF60-0552-41AE-A995-36A1373C27C5Q39502926-AFB3FA3D-5322-43B8-B482-F2FFE7830408Q39738226-74A1D77D-D2B9-41FD-91F6-6B51536911EFQ39898216-21D9F60C-4B21-4CA5-B4D8-5A39112F43AAQ39956341-A8E34717-4A81-422F-8FB2-267B89413B15Q40308949-F7809B67-7382-415D-A02D-F6858036F6E9Q40590744-F8FD0F37-49C0-4F3C-A511-86DBC05A3772Q40980796-B6284AEA-A290-4392-8975-13D3C9371EDDQ41992077-C9BFCC97-1AB7-4C1C-85FE-E09017A3DEFBQ41994917-B8B10AA1-339C-462D-AC4D-A7ED86452A2BQ42241116-ACE49400-C501-460B-8C23-3B5633C9EFFDQ42667053-2D8ED6A1-0CCA-4FA7-BEA0-38A24012FCE9Q43976211-4053B853-9E35-4D2B-91FB-96D446926D8BQ44084060-F3812417-CA91-4182-968C-7F468D387E86Q44157292-4C2CF190-DBD3-41E1-A17E-14E886830D06
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo Magni
@ast
Paolo Magni
@en
Paolo Magni
@es
Paolo Magni
@sl
type
label
Paolo Magni
@ast
Paolo Magni
@en
Paolo Magni
@es
Paolo Magni
@sl
prefLabel
Paolo Magni
@ast
Paolo Magni
@en
Paolo Magni
@es
Paolo Magni
@sl
P269
P106
P1153
55348245700
P21
P2456
P269
P31
P496
0000-0002-8931-4676